Ensuring Availability of Essential Medications and Addressing Constant Backorder Issues: The Texas Medical Association will work with the American Medical Association and the Federal Drug Administration (FDA) to (1) classify certain classes of drugs and biologics as critical for the practice of medicine; (2) create a mechanism, either by stockpiling certain drugs and biologics, or reducing regulatory hurdles that lead to the likelihood of sudden shortages; and (3) require manufacturers to provide six months’ advance notice of planned interruptions and prompt notification of unplanned disruptions. TMA will work with the AMA in reviewing the drug regulations of the FDA and other federal regulatory agencies that potentially create wholesale shortages of critical drugs and biologics, and require that a plan be in place to address that shortage prior to these regulations being implemented (Res. 311-A-12).
Last Updated On
October 07, 2016